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Liposomes are vesicular structures made of lipids that are formed in aqueous
solutions. Structurally, they resemble the lipid membrane of living cells. There-
fore, they have been widely investigated, since the 1960s, as models to study
the cell membrane, and as carriers for protection and/or delivery of bioactive
agents. They have been used in different areas of research including vaccines,
imaging, applications in cosmetics and tissue engineering. Tissue engineering
is defined as a strategy for promoting the regeneration of tissues for the human
body. This strategy may involve the coordinated application of defined cell
types with structured biomaterial scaffolds to produce living structures. To
create a new tissue, based on this strategy, a controlled stimulation of cultured
cells is needed, through a systematic combination of bioactive agents and
mechanical signals. In this review, we highlight the potential role of liposomes
as a platform for the sustained and local delivery of bioactive agents for tissue
engineering and regenerative medicine approaches.
1. Introduction
Lipids are hydrophobic or amphiphilic small molecules [1]. Therefore, they can
be classified as fatty acyls, glycerolipids, glycerophospholipids, sphingolipids,
sterol lipids, prenol lipids, saccharolipids and polyketides [2,3]. The amphiphi-
lic nature of some lipids allows them to form organized structures such as
vesicles or membranes, when immersed in an aqueous environment. They
can be extracted from plant- or animal-derived tissues by low-polarity solvents
such as chloroform.
Lipids play a vital role in physiological and pathophysiological events of
living systems [4]. It is believed that life started when nucleic acids were
enclosed within a membrane. The biological membrane separates nucleic
acids from the external environment and controls the transfer of information
and the transport of ions and molecules between the inside and outside of
the cellular membrane. A cell membrane is a complex and dynamic system
which consists of two lipid molecules held together by hydrophobic inter-
actions, and self-assembled as a continuous bilayer with proteins embedded
within the membrane or transiently associated with it (figure 1) [6].
This dynamic system is obviously necessary for life. The inner part of the
cell membrane aggregates the hydrophobic moieties of the lipids, and the
outside is hydrophilic. Integral proteins are usually in the hydrophobic core
of the bilayer [5]. Peripheral proteins are bound to the surface of the membrane.
The fluid mosaic model hypothesizes that the plasma membrane and organelle
membranes consist of proteins embedded in a fluid phospholipid bilayer. The
position of proteins is not static. Like the phospholipids in the bilayer,
membrane proteins are in constant motion [5]. Therefore, the cell membrane
allows the chemical reactions to occur much more efficiently in an enclosed
area and protects the genetic information. The main lipid biosynthetic organelle
is the endoplasmic reticulum which produces the bulk of the structural phos-
pholipids and cholesterol [7]. The most important lipid function in the
organism is their role in the plasma membrane.
& 2014 The Author(s) Published by the Royal Society. All rights reserved.
Glycerophospholipids, or phospholipids, are key com-
ponents of the lipid bilayer of cells [8–10]. Phospholipids,
together with membrane proteins and cholesterol, are
involved in many cell functions such as in the control of
cell shape, compartmentalization, the storage of compounds,
ion transport, metabolism, cell signalling processes and cell
fusion processes [10]. Phospholipids consist of a glycerol
which is linked to a phosphate group (PO422) and to two
fatty acids. In some cases, the phosphate group is bonded
to another small organic molecule, such as a choline.
Figure 2 shows an example of a phospholipid and the main
parts of its composition. Further details of lipids and their
properties will be discussed in §2.1.
Phospholipids may be classified as natural or synthetic.
Natural phospholipids may be obtained from various sources
such as soya bean or egg yolk. In terms of the polar head-
groups, phospholipids are classified as phosphatidylcholine
(PC), phosphatidylethanolamine (PE), phosphatidylserine
(PS), phosphatidylinositol (PI), phosphatidylglycerol (PG)
and phosphatidic acid (PA). PC and PE are the most abun-
dant phosphatides in plants and animals and are also the
most used to produce liposomes [12]. However, natural
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Figure 1. A cell membrane is a fluid with various proteins attached to the lipid bilayer. Adapted from [5]. (Online version in colour.)
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Figure 2. Chemical, three-dimensional and schematic structure of L-a-phosphatidylcholine, hydrogenated (soy) (HSPC) composed of fatty acid chains, glycerol
backbone and the headgroup (choline). Adapted from [11]. (Online version in colour.)
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phospholipids are less stable than the synthetic phospholi-
pids [13]. Synthetic phospholipids can be produced from
natural lipids. The modification of the non-polar and polar
regions of phospholipid molecules allows the creation of an
unlimited variety of well-defined and characterized phos-
pholipids [13]. Examples of synthetic lipids are dipalmitoyl
phosphatidylcholine (DPPC), dimyristoyl phosphatidylcholine
(DMPC), distearoyl phosphatidylcholine (DSPC) and hydrogen-
ated soy phosphatidylcholine (HSPC), 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC), (1-palmitoyl-2-stearoyl(5-
DOXYL)-sn-glycero-3phosphocholine (SLPC), 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-
phospho-(10-rac-glycerol) (DSPG), 1,2-dipalmitoyl-sn-glycero-3-
phosphoglycerol (DPPG) and 1,2-distearoyl-sn-glycero-3-phos-
phate (DSPA).
Sterol lipids, such as cholesterol (Chol) and its deriva-
tives, are hydrophobic lipids that have an important role in
the animal cell membrane [7]. Steroids are a family of lipids
distinguished by the four-ring structure shown in figure 3.
The various steroids differ from one another by the functional
groups or side groups attached to those rings. Chol is distin-
guished by a hydrocarbon ‘tail’ formed of isoprene subunits.
It is an important component of plasma membranes in many
organisms. In mammals, it is also used as the starting point
for the synthesis of several of the signalling molecules
called hormones. Oestrogen, progesterone and testosterone
are examples of hormones derived from Chol [14].
Compounds that contain both hydrophilic and hydro-
phobic elements are referred as amphiphilic. The amphiphilic
nature of phospholipids is of utmost importance for their bio-
logical function [14]. Specifically, this structure is responsible
for their presence and functional role in cellular membranes.
Phospholipids spontaneously self-assemble into ordered lyo-
tropic liquid-crystalline phases in the presence of water [10].
The formation of these lipid-based structures depends on the
phospholipid intrinsic factors, such as the nature and size of
the lipid headgroup and the length and degree of unsaturation
of the acyl chains, and on the extrinsic factors, such as tempera-
ture, pH, concentration and the presence of solutes and other
lipids [7,10]. Examples of lipid-based structures are mono-
layers, lipid bilayers, micelles, liposomes and tubules [7,15].
Herein, we will review the use of lipids to form liposomes
and discuss some of their applications, mainly focusing in
tissue engineering (TE) and regenerative medicine.
2. Liposomes
Liposomes are self-assembled vesicles that have the ability to
encapsulate aqueous solutions and hydrophobic compounds.
They are considered the oldest nanocarrier systems, which
were first discovered in the mid-1960s by A. D. Bangham [16].
Bangham performed experiments to determine how lipids
behave when immersed in water. When transmission electron
microscopes became available, Bangham was able to obtain
high-resolution images of the lipid–water mixtures. The
images showed that lipids formwater-filled vesicles, resembling
cells, which he called liposomes [14]. For further details about
the development of liposomes, the reader is directed to a
recent review that cites the significant contributions of the
early pioneers in the liposome field [17]. Since their discovery,
a large number of studies have been carried out to understand
their biophysical and biochemical properties, and possible
applications. They have been used as:modelmembrane systems
to study the basic nature of cell membranes [6], in biochemistry
and molecular biology [6,18], in analytical methods [18], in
microfluidic technologies [19], as a template for the production
of nanogels [20], in cosmetics and food technology [21,22],
in imaging [23], as drug delivery systems in pharmacology
[24–26], and in TE [27]. In this section, we will revisit
the liposome properties, their formulation/functionalization,
preparation methods and stability.
2.1. Liposome properties
Liposomes are spherical lipid bilayers with diameters ranging
from the nanometre to the micrometre scale [28]. Liposomes
have different advantages when compared with other alterna-
tive carrier systems [29,30]. One of the main advantages is the
fact that they are made of natural materials, i.e. lipids, and they
can be easily synthesized in the laboratory.
The properties of the liposomes are mainly dependent
on the characteristics of the lipids. A phospholipid has a
headgroup, a glycerol backbone and two fatty acid chains
(the so-called tails), as described above and depicted in
figure 2. One of the oxygen groups of phosphoric acid may
be esterified to a variety of organic molecules including
glycerol, choline, ethanolamine, serine and inositol. Examples
of negative lipids are PG, PS, PI and PA. Other lipids, such
as 1,2-dioleoyl-3-dimethylammonium-propane (DODAP)
and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP),
are mixed with neutral phospholipids to produce positively
charged liposomes [3]. The nature of the phospholipid is also
related to the length of the fatty acid chains. Therefore, the
fatty acids differ in the number of carbon atoms and the
degree of unsaturation [3]. When a double bond exists between
two carbon atoms (C ¼ C) in a hydrocarbon chain, the chain is
said to be unsaturated, whereas hydrocarbon chains without
double bonds (i.e. C – C) are said to be saturated. The length
and degree of saturation of the lipid chain influence the gel
liquid-crystalline phase transition temperature, Tc (table 1).
Considering the number of carbon atoms, the fatty acid can be
named as lauric (C12), myristic (C14), palmitic (C16) and stearic
(C18). In general, unsaturated fatty acids occur in natural
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Figure 3. Chemical, three-dimensional and schematic structure of cholesterol (Chol). Adapted from [14]. (Online version in colour.)
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phospholipids such as PC. DPPC, DMPC, DSPC and HSPC are
the most common synthetic phospholipids.
In aqueous environments, the lipids tend to self-assemble
into vesicles. Interactions between themselves, hydrophilic
interactions between polar headgroups, van der Waals inter-
actions between hydrocarbon chains and also with water
(hydrophilic interactions and hydrophobic effect) lead to
the formation of lipid-based structures such as liposomes
and micelles (figure 4) [32]. Micelles are tiny droplets created
when the hydrophilic heads of phospholipids face the water,
and the hydrophobic tails cluster together to hide from the
water molecules. Phospholipids with compact and short
tails tend to form micelles. Phospholipids with longer tails
tend to form liposomes (lipid bilayer with two sheets of phos-
pholipid molecules). The head of the phospholipid could
contain highly polar covalent bonds, as well as positive and
negative charges. Typically, these charges and polar bonds
of the head interact with water molecules, when a phos-
pholipid is placed in a solution, whereas the fatty acid tails
of a phospholipid do not interact with water (non-polar),
which means that they do not form hydrogen bonds with
the hydrocarbon tail [14].
The relative fluidity and the mobility of each lipid mol-
ecule within the bilayer constitute important properties of
the liposomes. The lipid bilayer has the tendency to allow a
given substance to pass across it—the so-called selective per-
meability [32]. This means that the internal environment of a
liposome can become different from the outer space. Indeed,
this capacity to keep different environments between external
and internal space is also one of the main characteristics of
cells [14,15].
As previously mentioned, the liposomes comprise highly
selective membranes (figure 5). Small non-polar molecules
move across the lipid bilayer quickly, whereas large mol-
ecules and charged substances cross the membrane slowly
[14,33]. Additionally, water molecules and ions are also
capable of moving across the lipid bilayer. Basically, water
moves across lipid bilayers from regions of high concen-
tration to regions of low concentration by osmosis. The
solutes move by diffusion from a region of high concentration
to a region of low concentration [14]. A comparison between
glucose and sucrose permeability indicates that the smaller
molecules (glucose) diffuses faster than larger molecules
(sucrose) by two orders of magnitudes [33]. Comparing the
diffusion of glucose and ions, glucose being a larger mol-
ecule, its permeability coefficient is approximately 6.40 to
250 times higher than Cl2, Kþ and Naþ. The permeability
of the lipid bilayer is very sensitive to the charge of the ion,
being larger in the case of Cl2 by more than one order of
magnitude compared with monovalent cations [33]. More-
over, liposomes have low permeability to hydrophilic
molecules and high permeability to hydrophobic molecules
[17]. More details about the release kinetics of bioactive
agents from liposomes will be discussed in the section
‘Release of bioactive agents from liposomes’.
The degree of fatty acid saturation also affects the per-
meability of the lipid bilayers to specific molecules (figure 6)
[15]. Because C – H bonds have more free energy than C ¼ C
bonds, saturated fats have higher chemical energy than un-
saturated fats [14]. The double bonds create spaces among
the tightly packed tails. Consequently, lipid bilayers contain-
ing many unsaturated fatty acids have more gaps and may be
more permeable than bilayers with fewer unsaturated fatty
acids [14].
Another parameter that can affect the mobility of the
lipids within the bilayer is the temperature [34]. At a given
temperature, a lipid bilayer can exist in a gel- or fluid-phase
(figure 7). Depending on the lipid Tc, membranes composed
of different lipids can exhibit different fluidity levels at the
same temperature. The Tc of phospholipids depends on the
following: (i) the length of the acyl chain in the lipid;
(ii) the degree of saturation of the hydrocarbon chains in
the lipid; (iii) the ionic strength of the suspension medium;
and (iv) the type of the polar headgroup [36].
Lipid bilayers dominated by phospholipids with long and
saturated hydrocarbon tails should be stiffer and less permeable,
because the interactions among the tails are stronger, leading to a
high Tc. Indeed, hydrophobic interactions become stronger as
saturated hydrocarbon tails increase in length [37]. Additionally,
longer tail lipids have more area to interact [31,35,38]. Conver-
sely, unsaturated lipids have a significantly lower Tc than
saturated lipids [32].
After the formation of the liposomes, the movement of the
molecules within and across the lipid bilayer is influenced by
the temperature and the structure of the hydrocarbon tails
[14]. As illustrated in figure 7, at a temperature below the
Tc, phospholipids are in the gel phase, presenting low fluidity
and permeability to encapsulated monovalent and divalent
cations [15]. At this temperature, individual molecules
within the bilayer move slowly. As a result, the hydrophobic
Table 1. Crystalline phase transition (Tc) of some phospholipids. Adapted
from [31].
phospholipid
acyl chain length,
no. unsaturation Tc (8C)
DSPC 18 : 0, 18 : 0 55
HSPC 16–18 (mixture) 52
DPPC 16 : 0, 16 : 0 42
POPC 16 : 0, 18 : 1 27
SLPC 18 : 0, 18 : 2 216.7
DOPC 18 : 1, 18 : 1 221
DSPG 18 : 0, 18 : 0 53
DPPG 16 : 0, 16 : 0 41.1
DSPA 18 : 0, 18 : 0 58
micelle liposome
Figure 4. Alternative lipid-based particles: micelle and a liposome. (Online
version in colour.)
rsif.royalsocietypublishing.org
J.R.Soc.Interface
11:20140459
4
tails in the interior of the lipid bilayer pack together more
tightly [14]. At a temperature above the Tc, the phospholipids
are in a fluid phase and have high fluidity, but also relatively
low permeability [15]. Therefore, the individual molecules
within the lipid bilayer move rapidly. At a temperature
equal to Tc, the lipid bilayer increases the permeability by
several orders of magnitude. This phenomenon is attributed
to the presence of highly permeable interfacial regions
between coexisting gel and fluid bilayer domains [15,39].
As previously described, cholesterol and its derivatives are
typically included in the liposome preparation. Therefore, the
presence of Chol has a great influence on the properties of the
lipid bilayers [31,33]. Specifically, the addition of Chol to a
lipid bilayer decreases its fluidity and permeability to water
within the fluid phase. The Chol molecule orients itself
among the phospholipid molecules, with its hydroxyl group
facing the water phase, the tricyclic ring sandwiched between
the first few carbons of the fatty acyl chains, into the hydro-
carbon core of the lipid bilayer [3]. Because the steroid rings of
Chol are dense, adding Chol to a lipid bilayer should increase
the density of the hydrophobic section. This decreases the flexi-
bility of the surrounding lipid chains, increases the mechanical
rigidity of the fluid bilayers and decreases their lateral diffusion
(figure 7). Additionally, Chol can inhibit the crystallization of
the hydrocarbon chains of saturated lipids to form a gel-state
system [33,36]. Itwas observed that the effect ofChol in decreas-
ing the permeability of Naþ, Kþ, Cl2 and glucose at 368C is
independent of the surface charge and headgroups [33]. The
permeability decreased by a factor of 4–18 for the cations, and
by only 2 for glucose and Cl2. The authors concluded that
Chol affects the process of dissolution more than the process
of diffusion [33]. Therefore, the addition of Chol to the lipid
bilayer modifies its molecular packing. The lipid bilayer
becomes more condensedwhen comparedwith pure phospho-
lipids above the Tc, and more fluid when compared with the
pure phospholipids below the Tc [33].
2.2. Formulation and functionalization
One of the main concerns in designing a liposome formula-
tion is the stability of the bioactive agent and of the lipid
components, which can be affected by the lipid concentration,
the environment, pH and temperature, and also their sus-
ceptibility to enzyme degradation. Additionally, the liposome
formulation depends on the bioactive agent to be encapsulated,
the preparation method, the phospholipid composition and the
intended application. Liposome formulations composed of
phospholipids andChol are defined as ‘conventional liposomes’
(figure 8a). Conventional liposome pharmacology and tissue
distribution depend on the size, surface charge and membrane
packing density [31]. For encapsulation of hydrophilic bio-
active agents, Chol and saturated phospholipids are the most
small, non-polar molecules
O2, CO2, N2
small, uncharged polar molecules
H2O, glycerol
ions
Cl–, K+, Na+
large, uncharged polar molecules
glucose, sucrose
low permeability
high permeability
Figure 5. Selective permeability of lipid bilayers. Adapted from [14]. (Online version in colour.)
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Figure 6. Unsaturated and saturated hydrocarbons. A double bond in a
hydrocarbon chain creates spaces in the double layer. Adapted from [14].
(Online version in colour.)
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important factors that allow the membrane permeability to be
reduced [31]. Cholesterol is commonly used in combination
with phospholipids, because Chol can make liposome mem-
branes stronger, as previously explained. The mole percentage
of Chol within the liposome composition is commonly not
more than 50% [12]. The hydrophobic interactions of Chol
with membrane lipids forces phospholipid headgroups to
shield Chol from water [40]. Cholesterol is necessary for the
stabilization and maintenance of the bioactive agent in the core
of the liposome, and this effect decreases with the increase in
the temperature [33].
The discovery in 1990 of the steric stabilization was one of
the main advances in the development of liposomes [17].
Coating the liposomes with hydrophilic polymers such as
polyethylene glycol (PEG) changes their surface properties
[41]. The liposome formulations composed of phospholipids,
Chol and PEG are defined as ‘sterically stabilized liposomes’
(SSLs), also called ‘stealth’ liposomes, or PEGylated liposomes
(figure 8b) [31,42]. It is known that PEG chains grafted onto
lipid membranes act like polymeric chains grafted onto solid
surfaces, stretching into brushes with increasing surface den-
sity. Based on this concept, it is believed that the PEGylated
surface provides a steric barrier that prevents the adsorption
of proteins onto the liposome surface [31,42]. Numerous
formulations of SSLs have been described for the systemic
delivery of bioactive agents [25]. However, this surface
gel phase
gel phase
fluidity
permeability
fluidity
permeability
fluidity
permeability
fluidity
Chol
T = TcT < Tc T > Tc
permeability
fluidity
permeability
fluid phase
fluid phase
Figure 7. Effect of temperature and Chol on phospholipid bilayer permeability. Chol eliminates the transition phase of the lipid bilayer. The Chol increases the lipid
bilayer permeability in the gel phase and decreases it in the fluid phase. Adapted from [15,35]. (Online version in colour.)
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antibody
fluorophore
negatively or
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Figure 8. Cross section of a liposome: (a) conventional liposome; (b) SSL; (c) ligand-targeted liposome; (d ) fluorescent liposome and charged liposomes. (Online
version in colour.)
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modification revealed some limitations due to its degradation
under mechanical stress as a result of its ether structure and its
non-biodegradability, as well as the resulting possible accumu-
lation in the body [43]. Initially, it was believed that SSLs could
be non-immunogenic, but an immune response can be elicited
after subsequent administrations of PEGylated liposomes,
leading to a rapid blood clearance or undesirable side effects
[25,44]. Therefore, SSLs should be designed in a way that cir-
cumvents those PEG-associated limitations, mainly affecting
the blood circulation half-life and the intracellular bioavailabil-
ity [25,43,45]. A variety of synthetic and natural polymers such
as poly(amino acid)s, heparin, dextran and chitosan were also
proposed to replace PEG [43].
The effective delivery of bioactive agents towards target cells
still represents an enormous challenge. One of the most promis-
ing strategies involves the covalent attachment of a ligand at the
extremity of PEG chains grafted onto the liposome surface,
which is intended to interact with antigens or receptors overex-
pressed at the surface of the target cells [46,47]. Antibodies and
antibody fragments are the most widely used moieties/ligands
due to the high specificity for their target antigens [28]. This
has led to a new class of nanocarriers called ligand-targeted lipo-
somes [48,49]. The conjugation of antibodies can be donedirectly
either to the lipid bilayer of the liposomes in the presence or
absence of PEG chains or to the distal end of the PEG chain
(figure 8c). The former, antibody-targeted liposomes are rapidly
cleared from the circulation, which limits their in vivo bio-distri-
bution. PEG could eventually be used to overcome this
limitation. However, when antibodies are attached at the lipo-
some surface, their antigen binding may be masked by the
presence of PEG in the same liposome, especially when longer
chain PEG molecules are used. Thus, the latter strategy, coupl-
ing of ligands to the terminus of PEG molecules engrafted into
the liposome surface, is the most used [17]. Trojan horse lipo-
somes are brain transport vectors that include endogenous
peptides,modifiedproteinsandpeptidomimeticmonoclonal anti-
bodies [49]. These liposomes target specific receptor/transport
systems of the brain capillary endothelium and undergo
receptor-mediated transcytosis through the blood–brain barrier.
Fluorescent lipids are also used in the liposome for-
mulations (figure 8d ). Liposomes carrying encapsulated
fluorophores have been synthesized as novel fluorescent
markers to image flow profiles in micro-fabricated structures
[19]. Fluorescent-labelled lipids are incorporated within the
lipid bilayer, and they have the following function: trigger
rapid membrane fusion, enable fluorescence imaging of cell
membranes and membrane traffic processes [50]. Moreover,
negatively and positively charged lipids are also added to
the liposome formulation to help in the liposome stabilization
and avoid agglomeration [51].
Liposomes of DSPC/Chol (3 : 2) extruded through 400 nm
filters were cleared 7.5 times faster than liposomes extruded
through 200 nm filters, which in turn are cleared five times
faster than small unilamellar vesicles (ULVs) [52]. The clearance
of liposomes containing PEG-PE of different sizes (less than
70 nm, 150–200 nm and more than 300 nm) was investigated
[53]. It was found that larger liposomes (more than 300 nm)
and small liposomes (less than 70 nm)weremore rapidly cleared
from the circulation than the liposomes of size 150–200 nm [53].
In another study, the clearance was unaffected by the Chol
content of the liposomes [54]. Liposomes of different compo-
sition with a particle size of about 90 nm were prepared
using DSPC, Chol and cholesten-5-yloxy-N-(4-((1-imino-2-D-
thiogalactosylethyl) amino) butyl) formamide (Gal-C4-Chol),
and labelled with [3H] cholesterol hexadecyl ether [55]. DSPC/
Chol/Gal-C4-Chol (60 : 35 : 5) liposomes exhibit extensive hepa-
tic uptake when compared with DSPC/Chol (60 : 40) liposomes
[55]. Kawakami et al. [56,57] synthesized amannosylated choles-
terol derivative (Man-C4-Chol) for mannose receptor-mediated
gene transfection to macrophages, and they studied the effect
of the lipid composition of mannosylated cationic liposomes
on in vivo transfection of plasmid DNA (pDNA). pDNA
complexed with Man-C4-Chol liposomes showed higher trans-
fection activity than that complexed with conventional cationic
liposomes using mouse peritoneal macrophages. Therefore, the
transfection efficiency of pDNA complexed with Man-C4-Chol
liposomes was inhibited in the presence of mannose, suggesting
that the complexes of pDNA and mannosylated cationic lipo-
somes are recognized and taken up by the mannose receptors
on macrophages. The liposome formulations, Man-C4-Chol
(1/0.5/0.5), Man-C4-Chol/DOPE (3/2) and DOTMA/Chol
(1/1), complexed with pDNA-encoding luciferase gene
(pCMV-Luc) were compared by intravenous and intra-portal
injections in mice. The highest gene expression was observed
in the lung using the control cationic DOPE/Chol liposomes
with both routes. Man-C4-Chol/DOPE liposome/DNA
complexes showed the highest gene expression in the liver
after intravenous and intra-portal injection. DOTMA/Chol/
Man-C4-Chol liposome showed the highest gene expression in
the liver by intravenous injection, but intra-portal injection
showed high expression in the lung [56,57].
2.3. Classification
Liposomes couldbe classified basedon themethodof their prep-
aration, by the number of bilayers present in the vesicle, or by
their size [3]. However, the classification of liposomes by the
number of bilayers and size are the most commonly used,
rather than by the method of their preparation. Based on the
number of bilayers and vesicles, the liposomes are classified
as ULVs (25 nm to 1 mm), or multi-lamellar vesicles (MLVs,
0.1–15 mm), or multi-vesicular vesicles (MVVs, 1.6–10.5 mm).
Furthermore, based on their size, unilamellar liposomes are
classified as large unilamellar vesicles (LUVs, 100 nm to 1 mm)
and small unilamellar vesicles (SUVs, 25–50 nm) (figure 9) [18].
2.4. Preparation methods
Many reports about the production of liposomes can
be found in the literature [3,16,37,58–62]. Common lipo-
some production methods include: thin-film hydration,
reverse-phase evaporation, ethanol injection, polyol dilution,
freeze–thaw, double emulsions, proliposome method, French
press extrusion, detergent removal and high-pressure hom-
ogenization [12,37,51]. These methods typically produce
LUVs or MLVs, depending on the selected method. Although
all these methods can be used to manufacture liposomes,
just three of them are usually used [63]: thin-film hydra-
tion, reverse-phase evaporation and the ethanol injection
method, which are described below. One of the main con-
cerns in liposome manufacturing is the toxicity related to
the organic solvents used. Several techniques have been
suggested for the removal of detergent and solvent traces
from liposomes. These techniques include gel filtration,
vacuum, centrifugation and dialysis [51]. A new method for
the fast production of liposomes without the use of any
hazardous chemicals or processes has been described. This
rsif.royalsocietypublishing.org
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method involves the hydration of the liposome components
in an aqueous medium, followed by the heating (up to 1208C)
of these components in the presence of glycerol (3% v/v)
[64,65]. For more details on this method for liposome
preparation, the reader is directed to the review in [51].
2.4.1. Thin-film hydration
The original method of Bangham is the simplest one when
compared with the other methods mentioned above [16,61].
It involves the use of volatile organic solvents, mainly chloro-
form, ether or methanol, to dissolve or solubilize the lipids.
The lipids are deposited as a thin film on the bottom wall of
a round flask, while the solvent is evaporated by a rotary
evaporation technique, under reduced pressure or a nitrogen
stream. An aqueous buffer is added to the deposited lipids,
allowing their hydration, at a temperature above the Tc of
the lipid or of the highest melting component of the mixture
[66]. Different MLVs can be produced depending on the
hydration time, the re-suspension method, the lipid concen-
tration and composition, and the volume of suspending the
aqueous phase [12]. When comparing the thin-film hydration,
the reverse-phase evaporation and the ethanol injection
methods to prepare cationic liposomes, the results showed
that liposomes prepared by the thin-film method were of the
best quality and stability [63]. This liposome preparation
method also presents some limitations such as low encapsula-
tion ability and the difficulty in producing nano-size
liposomes. However, sonication or extrusion through polycar-
bonate membranes can be employed to obtain ULVs [12,18,51].
2.4.2. Reverse-phase evaporation
In thismethod, the liposomes are formed fromwater-in-oil emul-
sions of phospholipids and buffer, in an excess of an organic
phase. Thephospholipids are firstlydissolved inorganic solvents
to forma film, then the solvents are removed byevaporation. The
thin film is re-suspended in diethyl ether, followed by the
addition of water. The preparation is then sonicated during a
brief time period, forming a homogeneous emulsion. The
organic solvents are removed under reduced pressure by contin-
ued rotary evaporation, resulting in the formation of a viscous
gel-like intermediate phase characterized by a LUV dispersion.
This method can encapsulate large macromolecules, with high
encapsulation efficiency (EE) (20–68%). The main disadvantage
of this method is the exposure of the material to be encapsulated
to organic solvents and to sonication conditions, which may
result in denaturation of sensitive molecules [12,66].
2.4.3. Ethanol injection
In this method, lipids dissolved in ethanol are rapidly
injected into a buffer solution, where they spontaneously
form SUVs, with a diameter of 30 nm [67]. However, the
size of the liposomes can be increased by increasing the
lipid concentration [66]. This liposome preparation method
has the advantage of avoiding chemical or physical treatment
of lipids. However, the concentration of vesicles produced is
low and it involves an extra step to remove ethanol [12].
2.5. Liposome characterization techniques
Methods of characterization of liposomes after production
and upon storage are required for an adequate quality control
[3]. Additionally, the chemical and physical characteristics of
the liposomes allow their in vitro and in vivo behaviour to be
predicted [31,68,69]. The main properties used to characterize
the liposomes include the average diameter and the poly-
dispersity index, the EE, the ratio of phospholipids to drug
concentration and the lamellarity determination [69]. The
average size and size distribution of liposomes are important
parameters especially when the liposomes are intended for
therapeutic use by the inhalation or parenteral routes [69].
For instance, small liposomes can pass through the fenestrae
of the liver sinusoids and can circulate in the body for
long time periods. Conversely, large liposomes are quickly
cleared by macrophages [31]. Therefore, the potential thera-
peutic application of a given liposome is highly influenced
by its average size and, consequently, by the possible
liposome–cell interactions at the target sites of action.
Table 2 lists some techniques used to physically character-
ize the liposomes, in terms of the size distribution and zeta
lipid bilayer
MLV MVV ULV
LUV SUV
Figure 9. Lipid bilayer structure and types of liposomes: MLVs, MVVs, ULVs.
Additionally, ULVs can be sub-classified as LUVs and SUVs. Adapted from
[18]. (Online version in colour.)
Table 2. Liposome physical characterization techniques.
physical
characterization technique references
size distribution DLS
static light scattering
gel exclusion
chromatography
light microscopy
laser diffraction
TEM
AFM
CLSM
small-angle X-ray
scattering
flow cytometry
field-flow fractionation
[68–70]
zeta potential LDE
capillary electrophoresis
[68,71]
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potential. Dynamic light scattering (DLS), sometimes referred
to as photon correlation spectroscopy or quasi-elastic light
scattering, is a technique enabling the measurement of the
size of particles in the sub-micrometre range [72]. Typically,
particle size measurements are taken between 2 and 5 min,
which allows DLS to be classified as a rapid technique. To
proceed with DLS analysis, the particles (up to tens of thou-
sands) are suspended in a solution and illuminated by light
in order for the particles to scatter light in a given index of
refraction, different from that of the suspending solvent [3].
Therefore, liposomes are measured in their natural state,
without the need for dehydration or staining.
Microscopic techniques such as atomic force microscopy
(AFM), environmental scanning electron microscopy (ESEM),
transmission electron microscopy (TEM) and confocal laser
scanning microscopy (CLSM) can give more information
about the nanoscale structures of liposomes. They can provide
information regarding shape and morphology (i.e. by AFM
and TEM), dimensions (by AFM, ESEM, TEM and CLSM),
surface properties ( just by AFM) and internal structure
(only by CLSM) [70]. When comparing all these microscopy-
based techniques, electron microscopy (i.e. ESEM or TEM)
requires the specialized freeze fracture technique, which is
prone to introduce distortion and artefacts from sample
preparation, and the need to have hundreds of photographs
in order to provide comparable statistics, constituting
time-consuming techniques [69].
The zeta (z)-potential is used to measure the intensity of
the repulsive electrostatic interaction between naturally
charged colloidal particles [73]. Indeed, measurements of
zeta potential are commonly used to predict the stability of
colloidal systems. If all the particles in a suspension have a
large negative or positive zeta potential, they will tend to
repel each other and, therefore, there will be no tendency to
aggregate. Typically, particles with zeta potentials more posi-
tive than þ30 mV or more negative than 230 mV are
considered stable [69]. However, if the particles have low
zeta potential values, then there will be no force to prevent
the particles from flocculating [69].
Laser Doppler electrophoresis (LDE) is the most widely
used technique to measure the zeta potential. In this tech-
nique, a laser is used to provide a light source, illuminating
particles within the samples. The incident laser beam
passes through the centre of the sample cell and the light is
scattered at a determined angle, which is detected. When
an electric field is applied to the cell, any particles moving
through the measurement volume will lead to fluctuation of
the detected light with a frequency proportional to the par-
ticle speed. This information is passed to a digital signal
processor and, then, the zeta potential is calculated [69].
This technique has been used to investigate how particle
size changes as a function of any parameter of the prep-
aration. It is used to monitor the effect of medium changes,
e.g. pH, temperature, surfactant, blood serum, adsorption
of proteins, and to develop formulations that resist aggrega-
tion/flocculation. It also enables the thickness of coatings at
the surface of the liposomes to be measured. It has been
widely used to predict the effectiveness of the liposomes’
coating against opsonization in vivo [74]. Moreover, it gives
information about whether the active agent used is encapsu-
lated or adsorbed at the surface of liposomes. For instance,
one can obtain information about DNA–liposome inter-
actions, DNA–peptide interactions and DNA condensation
during liposomal encapsulation, tracking the changes in size
of liposome–drug complexes [74–76]. However, there are sev-
eral factors that can affect the zeta-potential, such as pH,
conductivity and concentration of a formulation component.
2.6. Liposome limitations
Liposomes have been widely used as carriers to encapsulate
and to protect bioactive agents from the surrounding environ-
ments. Indeed, liposome drug products were the first type of
therapeutic nanoparticles being introduced in the market
[77]. For instance, Doxil, a doxorubicin-loaded liposome, was
approved by the US Food and Drug Administration in 1995
for treatment of Kaposi’s sarcoma [77]. In spite of the success-
ful clinical application and of the advantages of this drug
carrier, liposomes also present limitations, namely their low
stability, low solubility, short circulation half-life, susceptibility
to lipid oxidation and hydrolysis, leakage and fusion, reprodu-
cibility, difficulties in scaling up, high production costs and
sterilization issues [62,78].
Stability is the main concern in all steps of liposome
production, storage and administration, and includes the exam-
ination of: (i) the chemical stability of the lipids; (ii) the
maintenance of the vesicle size and structure; (iii) the retention
of entrapped contents; and (iv) the influence of biological fluids
on the integrity and permeability properties of the liposomes
[66]. Chemical and physical stability are important parameters
that affect the biological performance of liposomes [12]. The
physical stability of liposomes is mainly related to possible
aggregation/agglomeration, fusion and their content leakage
to the surrounding environment [31]. Liposomes stored under
sterile conditions, in phosphate-buffered saline under nitrogen,
can retain their entrapped bioactive agent for extended periods
of time [66].The relative retention of a bioactive agent depends
on the liposome type (i.e. MLV. reverse-phase evaporation
vesicle. SUV), the temperature (i.e. 48C. 258C. 358C) and
lipid composition (i.e. saturated phospholipids. saturated
phospholipids with equimolar cholesterol. unsaturated
phospholipids with equimolar cholesterol. unsaturated phos-
pholipids) [66]. Lipids can suffer auto-oxidation, which is
usually induced by light, metal ions or temperature. Addition-
ally, the hydrolysis of the phospholipids to fatty acids and
1- and 2-acyl-lysophospholipids leads to the production of
glycerol phosphor compounds and causes chemical degra-
dation of the liposomes during storage [79]. Antioxidants,
complexing agents (e.g. EDTA) and inert atmosphere (e.g.
nitrogen) are commonly used to avoid hydrolysis of the phos-
pholipids. Other ways to overcome problems concerning the
chemical decomposition of liposomes is their storage in a dry
state (i.e. freeze dried), using a cryoprotectant. For example,
addition of trehalose, which replaces water during the freeze
drying, is effective in preventing fusion and dehydration
damage in phospholipid vesicles [80].
Initially, it was assumed that, as liposomes were primarily
made of natural lipids such as PC, they would avoid the mono-
nuclear phagocyte system clearance and would not be
recognized as an antigen. However, it was realized that lipo-
somes would be accumulated in organs such as liver and
spleen, and cleared by macrophages (immune system), and
the clearance was related to the composition and the size of
the liposomes [31]. Therefore, this could be an advantage
when those organs or cell populations are the intended target
[36]. However, when other organs and cell populations are
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the target, this represents a main obstacle. Since this discovery,
the goal has been to design new liposome formulations to
bypass the immune system. Therefore, the physiological con-
ditions of the body should be taken into consideration when
designing a liposome formulation for a specific cell or organ
target when the liposomes are injected intravenously [29].
Currently, there are numerous methods available for
laboratory-scale production (§2.4), but only a few large-
scale manufacturing techniques are available [62]. Liposome
manufacturing involves numerous unit operations which
are not easy to scale up to commercial production levels
[78]. Therefore, all the large-scale manufacturing techniques
have serious limitations in terms of entrapment of sensitive
molecules, exposure to mechanical and/or chemical stress,
temperature and sterilization conditions. A detailed review
of liposome technology aimed at industrial-scale production
can be found in [62]. Currently, there is no established con-
sensus regarding the liposome manufacturing methods.
Solvent extraction systems require significant investment
and are very expensive to operate and maintain. The most
used method to achieve sterility for pharmaceutical products
is sterile filtration using a polycarbonate membrane [78].
However, this method has disadvantages; for example, it
needs to be performed under aseptic conditions, it is rela-
tively expensive as it operates under high pressure, it is
time consuming and it is not effective in removing virus [78].
3. Bioactive agent delivery
3.1. Loading liposomes with bioactive agents
The main advantages of liposomes as a bioactive agent deliv-
ery system are: (i) they have a versatile structure which can be
tailored for each application; (ii) they can accommodate any
type of bioactive agents either in their inner compartment
(i.e. hydrophilic molecules) or within the lipid bilayer
(i.e. lipophilic molecules) or both (amphiphilic molecules);
(iii) their nanoscale properties determine the solubility, diffu-
sivity, bio-distribution and biological fate; (iv) they are
minimally toxic, non-immunogenic and fully biodegradable;
(v) they are flexible to link with site-specific ligands to
achieve active targeting; and (vi) they increase the efficacy
and therapeutic index of bioactive agents [12,37]. Therefore,
the retention of bioactive agents within liposomes is
especially important, not only during storage but also
during in vivo administration [17].
The assembling of phospholipids into a hydrated bilayer
structure is coupled with the entrapment of a portion of the
aqueous medium within the continuous closed bilayer. There-
fore, it may seem that the encapsulation of bioactive agents
into liposomes should be a trivial process. However, there
are some limitations to the encapsulation of molecules into
liposomes, such as the type of bioactive agent (i.e. molecular
weight and chemical properties), the liposome (i.e. size and
lipid composition) and the manufacturing method. Selecting
bioactive agents with physical characteristics that make them
susceptible to retention into the liposomes is another approach
to control the loading and release rate [17]. There are two ways
to encapsulate bioactive agents into liposomes: passively,
when the bioactive agent is encapsulated during the liposome
formation; or actively, when the bioactive agent is encapsu-
lated after liposome formation [37]. The advantage of active
encapsulation is that the bioactive agent loading can be
performed independently of the time and site of liposome pro-
duction [3,17]. However, they can only be applied to a small
number of bioactive agents with specific physico-chemical
properties [12].
Pay load (PL) and EE are the terms used to determine the
amount of bioactive agent incorporated into the liposomes. PL
is the bioactive agent–lipid (mol mol21) ratio and EE is the
PL in the final liposome formulation compared with the initial
PL used for liposome preparation. Sometimes, the EE is used
to indicate the percentage of bioactive agent encapsulated in
relation to the amount of bioactive agent offered for encapsula-
tion during liposome preparation, but the amount of lipid is
not quantified. This quantification method is misleading, as it
highly depends on the initial amount of bioactive agent offered
to a specific lipid quantity [12] (figure 10).
3.1.1. Hydrophilic bioactive agents
These are dissolved in the external aqueous phase, during
liposome preparation, and become entrapped within the
inner compartment of the liposome after solvent evaporation
[81]. Thin-film hydration is the simplest method for the
encapsulation of hydrophilic bioactive agents. Encapsulation
becomes more difficult and inefficient as the size of the
bioactive agent increases, e.g. large plasmids [36]. Addition-
ally, the EE and bioactive agent-to-lipid ratios (i.e. PL)
achieved by thin-film hydration are low [36]. The percentage
of encapsulation of hydrophilic bioactive agent depends on
the size of liposomes: MLVs . LUVs . SUVs [82]. Also, the
liposome charge affects the entrapment of hydrophilic
bioactive agent: positively charged. negatively charged.
neutral liposomes [83]. The preparation of liposomes using
Chol lipophilic
drug
hydrophilic
drug
Figure 10. Representation of hydrophilic and lipophilic drug encapsulation
into the liposome. Hydrophilic drug is encapsulated in the inner core of
the liposome. Lipophilic drug is encapsulated into the lipid bilayer. Chol
and the lipophilic drug compete for the same space in the lipid bilayer.
(Online version in colour.)
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unsaturated phospholipids (e.g. DOPC) demonstrated a
higher EE than those liposomes using saturated phospholi-
pids (e.g. DPPC) [84]. The EE was more dependent on the
number of unsaturated bonds than on the alkyl chain
length of the phospholipid molecule [84].
To improve the EE of hydrophilic bioactive agents, it is
necessary to use different methods of liposome preparation,
such as reverse-phase evaporation, dehydration–rehydration
of empty liposomes and freeze–thaw cycling [36]. There are
other strategies to increase the EE of hydrophilic bioactive
agents into liposomes: by changing the pH and the ions and
creating ammonium sulfate gradients (also called active load-
ing) [3,17,85]. The development of these strategies for
improving encapsulation and retention of bioactive agents
into liposomes relies on experimental studies aimed at under-
standing the molecular factors governing the barrier
properties [85]. For example, bioactive agents that are weak
base/acid can diffuse through the lipid membrane and
accumulate into the inner compartment of the liposome
[85,86]. The ammonium sulfate gradient approach differs
from most other chemical approaches as it does not require
liposomes with an acidic interior or an alkaline extra-liposome
phase [86]. This approach has been used to encapsulate bio-
active agents inside the liposomes at high efficiency (more
than 90%) [86]. Moreover, to solve the problem of stabilization
of bioactive agents, one may increase the rigidity of the lipo-
some membrane, while concurrently decreasing their
tendency for aggregation by properly selecting the liposome
lipid components [12]. The use of a thin polymeric coating
made of chitosan or alginate may be a strategy to increase
the stability of bioactive agents into the liposomes [87–89].
However, the polymeric coatings may increase the size of
the liposomes and may also interact with the phospho-
lipid bilayer. Another strategy is to covalently cross-link
inter-lipid bilayers. For instance, cross-linked MLVs can
reduce systemic toxicity and improve therapeutic efficacy [90].
3.1.2. Lipophilic bioactive agents
In order to maximize the association of lipophilic bioactive
agents with liposomes, the most common practice is to mix
the lipids with the lipophilic bioactive agent and evaporate
the solvent to form a thin-lipid film. This mixture is re-
hydrated in the buffer and the liposome-associated bioactive
agent is separated from the free bioactive agent [66]. The inter-
action of such bioactive agents within the lipid bilayer
depends on the amount and structure of the lipophilic bio-
active agent, which results in alterations in the vesicle
properties such as permeability, size and stability of the bilayer
[91]. The encapsulation of lipophilic bioactive agents decreases
as the lipid chain length increases, and may destabilize the
liposomes [92]. Conversely, the addition of Chol increases
the rigidity and stability of liposome membranes, as was men-
tioned in the section on ‘Liposome properties’. However, if the
bioactive agent is lipophilic, it might be displaced by adding
Chol in the lipid bilayer. Therefore, the presence of Chol
decreases the encapsulation of lipophilic bioactive agents
[91,92]. A system has been proposed to enhance the EE of
lipophilic bioactive agents [93]. This consists of combining
liposomes and cyclodextrin–bioactive agent complexes by
forming bioactive agent-in-cyclodextrins-in-liposomes [93].
Cyclodextrins are hydrophobic inside and hydrophilic
outside, cavity-forming, water-soluble oligosaccharides that
can accommodate water-insoluble bioactive agents into their
cavities, increasing their water solubility. Therefore, the
water-soluble bioactive agent–cyclodextrin complex is capable
of being encapsulated within the aqueous compartments of
the liposomes. An EE of 32.3+11.9% for dehydroepiandros-
terone and 31.9+11.8% for hydroxypropyl-b-cyclodextrin
was achieved by using this method [12,93].
3.2. Release of bioactive agents from liposomes
Another critical issue when designing liposomes as bioactive
agent carriers is the control of the bioactive agents’ release,
which may dictate their therapeutic safety and efficacy. The
release kinetics is affected by the nature of the bioactive
agent, the liposome composition, the method of encapsula-
tion (i.e. passive or active) and the intended application
[12,94]. To understand the release of bioactive agents from
liposomes, we have to understand the structure of the lipo-
some and the possible interactions between the bioactive
agent, the lipid bilayer and the surrounding environment.
For example, encapsulation of dexamethasone (Dex) is
higher in DSPC liposomes than in PC liposomes, and Dex
is displaced from liposomes as the Chol content of liposome
membranes increases [55,91]. Also, a kinetic release study
performed in buffer or serum medium showed that the
release of Dex was provoked by the dilution of liposome
[91]. In another study, the release profile of Dex from the
DSPE–PEG-coated liposomes was performed in phosphate-
buffered saline using dialysis tubes for 21 days [55]. The
release profile of Dex showed an initial burst release within
12 h. Following the initial release, a slower release was
observed until day 6. Afterwards, Dex continued to be
released at a slower but steady rate until day 21 [55].
Bioactive agents (i.e. molecules or ions) encapsulated into
the liposomes tend to move spontaneously to the outer
environment of the lipid bilayer. The movement of molecules
and ions that results from their kinetic energy is known as
diffusion [14]. Therefore, the bioactive agent tends to move
from a region of high concentration to a region of low concen-
tration. This process depends on the type of bioactive agent
and the lipid composition [15,36,39]. For instance, when the
initial concentration of Ca2þ is high inside the liposome,
but low outside, heating to Tc results in immediate diffusion
of the Ca2þ into the medium [15,39]. Therefore, phospholi-
pids with high Tc may reduce the diffusion of ions and low
molecular weight molecules. The influence of the liposomal
composition on release of ibuprofen was investigated [95].
The long alkyl chain lipid enhanced ibuprofen EE and reten-
tion at 378C: dilignoceroyl phosphatidylcholine (C24PC) .
DSPC . DMPC. PC. After 30 min of incubation, PC lipo-
somes released 15.5% of the ibuprofen load compared with
1.5% for C24PC liposomes, and major differences in release
were evident after 24 h of incubation [95]. At 378C, both PC
(Tc , 08C) and DMPC (Tc ¼ 238C) liposomes were in the
fluid state resulting in an increasing amount of drug released
compared with the higher transition temperature lipids DSPC
(Tc ¼ 558C) and C24PC (Tc ¼ 808C). Therefore, C24PC lipo-
somes released less ibuprofen than DSPC liposomes despite
both systems being in the ordered gel phase. This behaviour
may be explained by the increased van der Waals interactions
between the longer lipid chains and the increased lipid phase
area within the liposomes enhancing the drug binding
and bilayer stability [95]. Moreover, the inclusion of charged
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lipids in the liposome formulations may influence bio-
active agents’ release. The addition of 2 mol of the anionic
lipid dicetylphosphate (DCP) reduced the EE and increa-
sed the release of ibuprofen (69.0+ 3.7%), and this was
explained by the electrostatic repulsive forces between
the carboxyl group of ibuprofen and the anionic head-
group of DCP [95]. The addition of 2 mol of the cationic
lipid stearylamine (SA) to the liposome formulation (PC :
Chol—16 mol : 4 mol) increased the EE by approximately
8–47% and also increased the release of ibuprofen (71.2+
2.8%) when compared with PC : Chol [95]. The authors
suggested that the electrostatic attraction between the posi-
tively charged head group in SA and the carboxyl group
present in dissociated ibuprofen appears to have little effect
on ibuprofen association with MLVs. Moreover, addition of
SA to the liposome formulation also resulted in a reversal
of surface charge (due to the cationic headgroup of SA) and
an increase in vesicle size of approximately 0.8 mm compared
with the unmodified PC : Chol formulation. This could be
the reason for the increase in the release of the drug.
These results indicate that the presence of charged lipids
(anionic or cationic) within the liposome bilayer increases
the permeability of the lipid bilayer and lipid–drug binding.
A successful treatment using bioactive agent-loaded
liposomes depends also on the route of administration (e.g.
subcutaneously, orally and intravenously). Conventional lipo-
somes, subcutaneously administrated, aim to target the
lymphatic system for imaging, distribution of therapeutic
agents or vaccination [12]. Moreover, conventional liposomes
may be developed to circumvent the endoplasmic reticular
system or to mask the toxic side effects of bioactive agents
[12]. Liposomes administered intravenously face barriers such
as the endothelial lining of the vasculature and the blood–
brain barrier. In those particular situations, it is important to
keep the bioactive agent in liposomes until they reach the
target site [36]. If the bioactive agent leaks out of the liposome
at a rapid rate, it will be lost before reaching the site of action,
and no therapeutic benefit will be obtained. On the other hand,
if the bioactive agent leaks out of the liposomes slowly, it
will be able to reach the site of action, but the levels of released
bioactive agent will never reach the desired therapeutic concen-
trations [36]. The low integrity of liposomes, after in vivo
administration and in contact with the blood components,
may result in removal of some lipid molecules and consequent
opening of pores into the liposome bilayer, through which the
loaded bioactive agent may leak out. Also, the physical
instability of liposomes that results in aggregation and fusion
may release the bioactive agent from liposomes [36]. For
example, neutral liposomes tend to aggregate and increase
the size of the liposomes [96].
The interaction of liposomes with cells is a critical aspect
of bioactive agents’ efficacy. In some clinical applications, the
bioactive agent has to be released inside the cells (e.g. tumour
cells) to have a beneficial therapeutic effect. In vitro and
in vivo studies have shown that the main interactions of
liposomes with cells are simple adsorption (by specific inter-
actions with cell-surface components, electrostatic forces, or
by non-specific weak hydrophobic forces) or following endo-
cytosis [37]. Many attempts to activate the release of bioactive
agents from liposomes in the vicinity of or inside the cells
have been described [17,97]. Active release relies on develop-
ing mechanisms to increase the permeability or to destabilize
the liposome bilayer once it reaches the target site. A variety
of stimuli such as pH [46,98], temperature [39,99], ultrasonic
waves [100], magnetic fields [101,102] and light [103,104] are
currently being investigated to improve the target release of
bioactive agent. Although the concept of triggered release is
very promising, more studies have to be performed to
prove its application in humans [17].
4. Applications of liposomes in tissue
engineering
In living organisms, the lipids are considered basic building
blocks, because they are formed of a polar headgroup, one
or more hydrophobic tail regions and a backbone structure
that connects the two [15]. Therefore, researchers have been
taking advantage of the characteristics and versatility of
lipids to find new applications [12,15]. Liposomes and
micelles are the most widely used lipid-based nanoparticles
[105]. Other lipid structures can be obtained such as cubic-,
hexagonal- or sponge-phase structures [106]. They offer the
advantage of stability and could be used as novel biomater-
ials mimicking biological membranes. It is believed that
phospholipid-based materials may be increasingly used as
tools for the manipulation of cell and tissue responses to
biomaterials, namely for the controlled release of bioactive
agents and for reconstructive surgery [15].
Nowadays, the most clinically used applications of lipo-
some-based therapy are in the treatment of cancer and of
systemic fungal infections [36]. However, the future of lipo-
somes is not limited to those therapeutic applications.
Liposomes, being a highly flexible platform, have been
used in different areas of research including the production
of vaccines, imaging, cosmetics and TE [27,36]. Herein, we
will focus on lipids as a biomaterial and review some appli-
cations of the liposomes, mainly in TE and regenerative
medicine. It is expected that therapeutic nanoparticles, such
as liposomes, offer the potential to dramatically improve
the effectiveness and side-effect profile of new and existing
bioactive agents [77]. Moreover, many tissue-engineered
scaffolds have already been approved for human use [27].
Therefore, combining liposomes with scaffolds has the
potential for clinical translation in the near future.
4.1. Combining liposomes with scaffolds
The field of biomaterials has been advancing towards the
nanoscale design of bioactive systems of drug release or scaf-
folding, aimed at TE and regenerative medicine strategies
[107]. The combination of drug-loaded nanoparticles with
scaffolds can be used to spatially and temporally control
the release of bioactive agents, leading to a sustained and
local delivery [108]. Over recent years, there have been an
increasing number of studies aiming to direct stem cell fate
through the delivery of growth/differentiation factors,
DNA or interference RNA (RNAi). The encapsulation of the
bioactive agents into nanoparticles such as liposomes has
many advantages, as described in the section ‘Loading
liposomes with bioactive agents’. However, the single use
of liposomes is limited due to the absence of a three-dimen-
sional mechanical support frequently required to promote
tissue regeneration [107].
Many types of scaffolds can be made of natural and/or
synthetic polymers, using different processing techniques.
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For an extensive analysis of the topic, the reader is directed to
reviews of TE scaffolding in [109–112]. TE scaffolds can be
designed to physically and chemically control the release pat-
tern of any incorporated bioactive agents [27]. Particularly,
hydrogels are a set of scaffolds that present an enormous
potential for application as smart and stimuli-responsive bio-
materials [113]. The delivery of bioactive agents from
scaffolds to promote regeneration is often challenging due
to the complex fabrication processes. For instance, bioactive
agents can be incorporated in the matrix or encapsulated
into hollow nanofibres [114]. When the bioactive agent is
incorporated in the matrix, there is a strong burst release
within the first few hours [115]. Therefore, when the bioactive
agent is encapsulated into hollow nanofibres, there is a better
control of the bioactive agent release profile, but some of the
complications during nanofibre preparation do not allow for
easy large-scale production [116].
The combination of liposomes with scaffolds has been
already reviewed elsewhere [15,27,108,117]. All these strat-
egies aspire to combine the advantageous properties of
liposomes and polymer matrices, aiming at developing
materials that can sequester and maintain liposomes at a
local tissue site. Stimuli-responsive liposomes have also
been used as devices to control chemical reactions, which
result in the rapid formation of a biomaterial such as the
in situ formation of minerals, polymers or mineral/polymer
composite biomaterials [15,118–121]. This exploits the release
of entrapped substances from liposomes at temperatures near
the lipid Tc (i.e. approx. 378C) (see figure 7; see also the
‘Liposome properties’ section) [39]. The liposome structure
is very sensitive to organic solvents, temperature and pH.
Therefore, many ways to immobilize liposomes at the scaf-
fold surface have been proposed [27,122–125]. There are
two ways to immobilize liposomes at the surface of the scaf-
folds: (i) non-specific immobilization, which means that the
liposomes are adsorbed at the surface of the scaffold and
are easily removed during the cell culture at each medium
exchange; (ii) specific immobilization, which means that the
liposomes are covalently bound at the surface of the scaffold,
increasing their stability. A scaffold system that uses naturally
occurring interactions between liposomes and the fibrinogen
was used to obviate the need for chemical conjugation [126].
To facilitate liposome adsorption, scaffold surfaces were
coated with various extracellular matrix proteins, which
were able to transfect a higher number of cells, while at the
same time reducing the amount of DNA required [127].
Recently, a chemical modification of electrospun polycapro-
lactone (PCL) nanofibre meshes (NFMs) was reported
enabling the immobilization of bioactive-loaded liposomes
onto their surfaces [124,125]. To achieve this, initial
UV-ozone irradiation was used to generate reactive free rad-
icals that were immediately subjected to aminolysis. These
modified surfaces were reacted with 2IT to generate sulfide
(SH) pendant groups. Dexamethasone and pDNA-encoding
RUNX2-loaded liposomes were covalently bonded to the
SH groups present at the surface of electrospun NFMs
[124,125]. The availability of the drug-release vehicle at the
surface of the NFMs (where initial cellular contact occurs)
enables a sustainable release of the Dex in the vicinity of
the cells in culture and, consequently, increases its efficacy
and bioavailability [125]. It was concluded that the amount
of liposomes immobilized is specifically controlled by the
amount of SH groups available at the nanofibres’ surface
[124,125]. Another strategy to combine liposomes and nano-
fibres is to use coaxial electrospinning. This technique
enables the incorporation of liposomes into nanofibres
[128]. Table 3 shows the applications of liposomes combined
with scaffolds for TE approaches.
Tissue regeneration depends not only on the bioactive
agent itself such as growth factors (GFs), but also on the var-
ious parameters associated with its presentation, including
concentration, spatio-temporal gradients, combination with
other GFs and the target cell type [151–154]. Bioactive
agent-loaded liposomes combined with scaffolds offer var-
ious intrinsic benefits such as: (i) effective concentration; (ii)
stable concentration gradients; (iii) multiple bioactive agent
delivery; and (iv) spatial patterning [27]. The bioactive
agent delivered by the liposome–scaffold device can be of
two types: (i) growth/differentiation factor, by the incorpor-
ation of the proper bioactive agent-loaded liposomes into the
scaffold; and (ii) nucleic acid delivery, by the incorporation of
the DNA (or RNAi) into liposomes that encodes (or silences)
a specific protein or by cell delivery, in which cells act as ‘GF
factories’. These types of local bioactive agent release system
will be discussed in §4.2.
4.2. Growth/differentiation factor delivery
The tissue regeneration process involves complex cascades of
bioactive agents such as GFs, cytokines and other molecules.
GFs are endogenous polypeptides that act through the
cell-surface receptors to regulate cellular activities such as
proliferation, migration and differentiation [155]. The out-
come of GF therapeutics mainly depends on their delivery
mode due to their rapid clearance in vivo [156]. Furthermore,
one of the main challenges in TE is to find the best way to
induce the correct differentiation of stem cells. So far, the
most common approach relies on the use of cocktails of
growth/differentiation factors supplemented in the culture
medium. For instance, bone morphogenetic protein 2 (BMP-2)
is added to induce the osteogenic differentiation, whereas
transforming growth factor b (TGF-b) is used to promote
the chondrogenic differentiation. An adequate combination
of signalling molecules should be provided by controlled
release systems in order to promote the desired regenerative
outcome [112,157–159]. Therefore, liposomes can be used
as carriers for the spatio-temporal controlled delivery of
GFs, improving stem cell proliferation and differentiation
in vitro [160,161].
Liposomes were used with some success in an animal
model for cartilage repair [143]. They were used as release
systems of TGF-b1 over a period of some weeks, avoiding
the typical side effects of systemic administration, due to its
direct injection into the joint cavity. Moreover, the conju-
gation of TGF-b1-loaded liposomes with a scaffold
improved its release kinetics and local efficacy [143]. Bisphos-
phonate-coated liposomes displayed a strong binding to a
collagen/hydroxyapatite (HA) composite scaffold, increasing
their retention in the collagen/HA scaffolds after their sub-
cutaneous implantation in rats [122]. The bisphosphonate-
coated liposomes were able to entrap BMP-2 and deliver it
locally [122]. The immobilization of fetal bovine serum-
loaded liposomes in a poly(2-hydroxyethyl methacrylate)
fibrous scaffold significantly improved chondrocyte adhesion
and proliferation [123]. The aim of this study was to investi-
gate the interaction between liposomes and fibre scaffolds
rsif.royalsocietypublishing.org
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and to develop a novel drug delivery system. The release pro-
file of Dex showed an initial burst release, although Dex
continued to be released at a slower but steady rate until
day 21 [55]. This time frame was selected in accordance
with the culture time usually required to obtain a complete
osteogenic differentiation of mesenchymal stem cells
(MSCs) in vitro. Dex-loaded liposomes did not have any cyto-
toxic effect on human bone marrow-derived mesenchymal
stem cells (hBMSCs). They were able to promote an earlier
induction of differentiation of hBMSCs into the osteogenic
lineage [55]. Biological assays showed that Dex-loaded lipo-
somes immobilized at the surface of electrospun PCL NFMs
did not exhibit any cytotoxic effect, being able to successfully
promote the osteogenic differentiation of hBMSCs [125].
4.3. Therapeutic gene delivery
The use of growth/differentiation factors to induce stem cell
differentiation in vivo has some limitations such as short
half-lives, denaturation during the encapsulation processes,
time-consuming, long time periods to obtain the differentiated
cells, use of cocktails of GFs and difficulty to differentiate the
cells into one specific lineage [108,162]. Therefore, gene
therapy, encoding transcription factors or encoding for a
specific or to a set of proteins may be a good approach to over-
come these limitations and to control stem cell differentiation
[124]. Transcription factors would ensure that expression of
all natural splice variants occurs in a coordinated time and
sequence, and may regulate a cascade of multiple different
genes. Gene therapy was initially envisioned as the insertion
of a functioning gene into the host cell genome to replace a
hereditary genetic defect or, more recently, to provide a new
function in a cell such as overexpressing GFs or even killing
cancer cells [36,148]. When the pDNA enters into the nucleus,
it is intercalated in the DNA of the host cell and, then, tran-
scribed into messenger RNA (mRNA). Therefore, therapeutic
proteins or GFs are produced using the cell machinery outside
of the nucleus.
Another way to control stem cell differentiation relies on
the delivery of RNAi, as previously mentioned [162]. RNAi
acts by binding to nucleic acids, inhibiting gene transcription
and translation; in other words, RNAi acts by silencing genes
of interest through the eradication of target mRNAs through
the introduction of small interfering RNAs (siRNAs),
small hairpin RNAs (shRNAs) or micro-RNAs (miRNAs)
[25,108,162]. The main advantage of this strategy is that the
RNAi induces the silencing of targeted genes without inte-
gration into the host genome. Therefore, this field has
grown considerably in the last decades, due to its huge poten-
tial to treat diseases by replacing defective or missing genes
or silencing unwanted gene expression [163]. Notable pro-
gress has been achieved by the delivery of miRNAs to
reprogramme somatic cells into pluripotent stem cells
(iPSCs), thus obviating the need to introduce pDNA into
donor cells [164].
The delivery of genes can be made by an ex vivo approach
or directly into a target cell or tissue. The ex vivo method gen-
erally uses autologous cells that are recovered from the
patient’s body. The cells are generally transduced with viral
vectors, containing recombinant genes, and re-inserted/
transplanted into the target tissue [148]. Likewise, pDNA or
RNAi is poorly taken up by the host cells, being subjected
to degradation when exposed to blood proteins [165]. Viral
and non-viral vectors are examples of carriers used to trans-
fect cells [166–168]. The widely used method to transfer
genes to stem cells is performed through viral vectors (i.e. len-
tivirus and retrovirus), because of their higher transgene
expression and transduction efficiency. Thus, when stem
cells are used to correct a genetic pathology and to express
the therapeutic gene for the duration of a patient’s life, viral
vectors are preferred [169]. Conversely, when stem cells are
used to treat non-inherited diseases and are only required
to express the therapeutic gene for a short period of time,
non-viral vectors are preferred [169]. Although viral vectors
are more efficient, they possess some limitations such as
high production cost, safety issues including mutagenesis,
the immunogenicity of the virus proteins, lack of desired
tissue selectivity and generation of infectious viruses due to
recombination [170–172]. Therefore, there is a need for a
delivery system that not only protects the pDNA/RNAi
and facilitates its cellular uptake, but additionally enhances
the potential for a targeted and effective delivery [165,169].
Non-viral delivery systems (i.e. liposomes, cationic lipids,
polymers and proteins) have comparatively lower transfec-
tion efficiency, but they have been proposed due to their
safety, easy production and higher pDNA size encapsulation
[27,108,162,172–174]. Moreover, non-viral vectors provide
flexibility in formulation design which can be tailored to
interact with the DNA cargo. Also, by incorporating targeting
ligands, it is possible to specify the route of vector adminis-
tration and enhance the delivery to specific tissues or cells.
Liposomes are considered the first non-viral delivery
system used in cell biology [27]. Cationic lipids have
emerged as the primary option for gene delivery [77,175].
Various cationic lipids were synthesized and evaluated for
the transfection of cells [175]. These cationic liposomes
show high transfection efficiency, which can be attributed
partly to their interactions with negatively charged cell mem-
branes [27]. Lipofectamine, a leading commercial reagent, is
a cationic liposome formulation commonly used to transfect
cells [176]. However, their success in vivo as a gene therapy
strategy has been limited due to the lack of colloidal stability,
short duration of gene expression and cytotoxicity [175,177,
178]. Cationic polymers have also been proposed as non-
viral gene delivery systems, due to their flexible properties,
facile synthesis, robustness and proven gene delivery effi-
ciency. For further details about the most recent scientific
advances in cationic polymers and their derivatives not
only for gene delivery purposes but also for various alterna-
tive therapeutic applications, the reader is directed to the
review in [179]. The use of liposomes combined with scaf-
folds may contribute to overcoming the issues of toxicity,
long-term expression and silencing efficiency. Specifically,
the topical delivery of gene-loaded liposomes via a biomater-
ial scaffold may reduce their exposure to immune cells,
enhance cellular uptake and possibly allow for a sustained
delivery [27,162].
Liposome–scaffold systems may be used as a biomaterial
to deliver genes in an efficient, cell-controlled and spatially
localizedmanner for TE applications. Bone and cartilage regen-
eration with a gene therapy strategy is one of the clinically
relevant applications [108]. Those strategies have focused on
the delivery of genes encoding BMPs and TGF-b that initiate
bone and cartilage progenitor cell differentiation, and coordi-
nate the pathways of newly formed bone ossification and
cartilage maturation [133,137,148,180]. Tissue vascularization
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was exploited by the delivery of genes encoding VEGF using
bone marrow stromal cells [181]. Liposomes loaded with
DNA encoding the 165 amino acid form of VEGF were injected
into rat skin stimulating wound healing [182]. The flap survival
was enhanced by 14%, and the histological analysis showed
new vessel formation [182]. A plasmid expression vector con-
taining VEGF was constructed to be administered to the
wound bed of rat abdominal skin flaps in a fibrin sealant
[145]. The topical fibrin-mediated administration of a VEGF-A
plasmid increased flap survival by 7 days. pDNA-encoding
RUNX2-loaded liposomes were covalently immobilized at the
surface of PCL nanofibres [124]. The biological result using
hBMSCs showed that hBMSCs cultured on RUNX2-loaded
liposomes immobilized at the surface of electrospun PCL
NFM showed enhanced levels of metabolic activity and total
protein synthesis. RUNX2-loaded liposomes immobilized at
the surface of electrospun PCL NFMs induce a long-term
gene expression of eGFP and RUNX2 by cultured hBMSCs.
Furthermore, osteogenic differentiation of hBMSCs was also
achieved by the overexpression of other osteogenic markers in
medium free of osteogenic supplementation.
4.4. Magnetite cationic liposomes
The main properties of magnetic particles are that they are
non-toxic and biocompatible, they can be injected and they
can eventually accumulate in the target tissue or organ by
the application of an external magnetic field [183]. They are
attracted to high magnetic flux density, which is used for
bioactive agent targeting and bio-separation including cell
sorting. Because of their small size (i.e. approx. 10 nm),
they can be encapsulated into the inner compartment of lipo-
somes (figure 11). Magnetite cationic liposomes (MCLs) are
magnetic nanoparticles, positively charged, that can interact
with the negatively charged cell membranes. They find
many applications such as in hyperthermic treatments and
in TE and regenerative medicine strategies [183]. Table 4 com-
piles some of the studies in which MCLs were used in TE
approaches. The application of magnetic nanoparticles and
magnetic force for TE is termed ‘magnetic force-based tissue
engineering (Mag-TE)’ [183]. For instance, MSC sheets created
by magnetic nanoparticle-containing liposomes may represent
a new modality for therapeutic angiogenesis and bone tissue
regeneration [193]. MCLs successfully facilitated cell seeding
into the interior space of the scaffolds [187].
4.5. Liposomes as templates
We have focused herein on the use of liposomes as a device
for the release of bioactive agents. However, liposomes can
be used as templates to produce polymeric nanoparticles
and nanogels (figure 12) [20,196,197]. In this approach, the
inner compartment of the liposome can be used as the reac-
tion vessel [15,196]. For example, the encapsulation of
sodium alginate was performed by the thin-film method.
Liposomes were extruded through a polycarbonate mem-
brane of uniform pore size followed by incubation with
high concentrations of calcium chloride. The diffusion of cal-
cium into the liposome interior resulted in alginate gelation
within the liposome of size 748+280 nm [197]. Another
study reported the production of alginate nanogels with a
size distribution between 120 and 200 nm [196]. Liposomes
were also used as a template to prepare monodisperse
PEG hydrogel nanoparticles [20]. The procedure for the
preparation of PEG nanoparticles using liposomes consis-
ted of the encapsulation of a photo-polymerizable PEG
hydrogel solution into the cavity of the liposomes, extrusion
through a polycarbonate membrane and photopolymeriza-
tion of the contents inside the liposomes by UV irradiation
(figure 12b). The size distribution of the prepared particles
was 94+12 nm after extrusion through the membrane with
pore size of 100 nm. This approach also enables the surface
of the hydrogel nanoparticles with functional groups to be
modified in a one-step procedure [20].
The ability to encapsulate a gel in the inner compartment
of liposomes using specific polymers has particular impli-
cations beyond drug delivery [198]. Specifically, it can
mimic a eukaryotic cell, which is considered to be a gel
enclosed within a lipid bilayer membrane. The gel may be
formed by the polymerization of cytoskeletal proteins such
as actin, filament and tubulin. Therefore, a liposome with a
gelled core might be a better study model of a biological
cell [199]. Moreover, it could also be used as a container for
single molecule fluorescence studies, e.g. for localizing a
single DNA or protein molecule within the interior.
The lipid–polymer hybrid (LPH) nanoparticles have also
been investigated to deliver therapeutic compounds in a con-
trolled manner [200]. These hybrid nanoparticles combine the
unique strengths of liposome and polymeric nanoparticles.
They may be used to overcome their limitations in terms
of bioactive agent EE, storage stability and release [200].
LPH nanoparticle synthesis requires the use of microfluidics
technology to improve the mixing process, but is restricted by
a low throughput. However, a pattern-tunable micro-vortex
platform can allow mass production and size control of LPH
nanoparticles, with superior reproducibility and homogeneity.
5. Concluding remarks
Liposomes are vesicular structures made of lipids that are
formed in aqueous solutions, and they resemble the lipid
membrane of cells. Since their discovery, a lot of research
has been carried out to achieve effective delivery of thera-
peutic bioactive agents, mainly in cancer research, with
some products now coming onto the market. However,
there are some limitations to overcome. For example, new
liposome-based formulations have to be developed to over-
come the rapid blood clearance of PEGylated liposomes.
The concept of triggered release is very promising and
Chol
magnetite
nanoparticle
cationic
lipid
Figure 11. Magnetite cationic liposome. (Online version in colour.)
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Table 4. Applications of MCLs.
applications achievements
year/
references
cell sheet with RGD-MCLs in TE coating the culture surface with RGD-MCLs facilitated cell growth, cell
sheet construction and cell sheet harvesting, using magnetic force
without enzymatic treatment
2005 [184]
three-dimensional tissue-engineered tubular structures tubular structures were constructed using magnetic force. Two types of
tissue were used to create tubular structures: urinary tissue and
vascular tissue
2005 [185]
cell sheet approach for choroidal neovascularization MCLs were used to construct and deliver retinal pigment epithelium cell
sheets in vitro. 15-layered cell sheets were formed after 24 h of culture
2005 [186]
enhancement of cell seeding into the deep internal
space of the scaffolds (collagen sponges and
polylactic acid sponge)
fibroblasts labelled with MCLs were seeded onto scaffolds. Cell-seeding
efficiency increased significantly in all scaffolds when compared with
those without magnetic force
2006 [187]
bone TE using bone marrow stromal cells and three-
dimensional HA scaffolds
magnetically labelled BMSCs were successfully seeded into the internal
space of scaffolds with a high cell density. The levels of alkaline
phosphatase and osteocalcin were significantly higher than those by
static seeding
2007 [188]
in vitro reconstruction of three-dimensional bone tissues
without the use of scaffolds
MSCs magnetically labelled with MCLs formed multi-layered sheet-like
structures after a 24 h culture period and maintained the ability to
differentiate into osteoblasts, adipocytes or chondrocytes after a 21
day culture period. Transplantation of the MSC sheets into the bone
defect in the crania of nude rats showed new bone formation
2007 [189]
incorporation of capillary-like structures into dermal cell
sheets
human umbilical vein endothelial cells co-cultured with magnetically
labelled normal human dermal fibroblast (NHDF) sheets showed
tube-like formation of human aortic endothelial cells, resembling
early capillaries, within or on the surface NHDF sheets
2007 [190]
effective cell seeding onto decellularized blood vessels
for vascular TE
cells labelled with MCLs increased the cell seeding into porcine
decellularized carotid artery scaffold. The scaffold was successfully
constructed with two human cells, smooth muscle cells and dermal
fibroblasts
2007 [191]
viral vector (VEGF) labelled with MCLs for fabrication of
angiogenic cell sheets
a retroviral vector encoding VEGF was labelled with MCLs, to
magnetically attract the particles onto a monolayer of mouse
myoblast C2C12 cells. Subcutaneous transplantation of C2C12/VEGF
cell sheets into nude mice produced thick tissues, with a high cell
density, and promoted vascularization
2010 [192]
MSC sheet for therapeutic angiogenesis and tissue
regeneration
human MSCs incubated with MCLs formed multi-layered cell sheets
according to magnetic force. MSC sheets layered onto the ischaemic
tissues of nude mice before skin closure showed greater angiogenesis
than the control and MSC injected
2011 [193]
construction of three-dimensional artificial skeletal
muscle tissues
MCLs were used to magnetically label C2C12 myoblast cells for the
construction of artificial skeletal muscle tissues by an applied
magnetic force. Elongated and multi-nucleated myotubes were
observed within the tissue
2011 [194]
iPS cell sheets for reparative angiogenesis mouse iPS cell-derived Flk-1(þ) cells were incubated with MCLs.
Implantation of the Flk-1(þ) cell sheet accelerated revascularization
of ischaemic hindlimbs relative to the contralateral limbs in nude
mice and increased the expressions of VEGF and bFGF in ischaemic
tissue
2013 [195]
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more studies are needed to validate its applicability in vivo, in
humans. Also, large-scale manufacturing methods and
technologies are required for marketed products providing
sterile, well-characterized and stable products.
In this review, we have highlighted some applications of
liposomes in TE and regenerative medicine. Liposomes can
be viewed as a platform to induce the differentiation of stem
cells through the release of bioactive agents (i.e. GFs or nucleic
acids). One of the main challenges in stem cell research is the
successful differentiation of stem cells into a specific lineage.
However, conventional methods to induce the overexpression
of lineage-specific proteins relies on the use of growth/
differentiation factor cocktails with sub-optimal outcomes.
Liposomes can control growth/differentiation factor release
and avoid their side effects. Another possible alternative
relies on the delivery of nucleotides (i.e. pDNA and RNAi).
The true potential of gene delivery is the possibility to guide
the stem cell fate in the absence of inductive factors. The
incorporation of pDNA into the host cells’ genome raises bio-
compatibility issues in the context of TE, where differentiated
cells are used for subsequent in vivo applications. RNAi may
be a possible alternative to guide stem cells’ fate without
incorporation of pDNA into the host cells’ genome. Cationic
liposomes are a possible alternative to transfect cells, but
they have a lower transfection efficiency [169]. The combi-
nation of liposomes with scaffolds represents a good
approach to overcome this limitation.
The efficacy of using liposome–scaffolds in TE and regen-
erative medicine is clear from the literature. However, the
potential of this strategy has to be investigated in order to
optimize liposome formulations and the best material for
the specific application. We believe that liposome–scaffolds
may enhance stem cell differentiation and bring novelties in
TE and regenerative medicine.
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